全文获取类型
收费全文 | 8077篇 |
免费 | 588篇 |
国内免费 | 55篇 |
专业分类
耳鼻咽喉 | 35篇 |
儿科学 | 175篇 |
妇产科学 | 165篇 |
基础医学 | 1368篇 |
口腔科学 | 191篇 |
临床医学 | 801篇 |
内科学 | 1797篇 |
皮肤病学 | 234篇 |
神经病学 | 937篇 |
特种医学 | 214篇 |
外科学 | 823篇 |
综合类 | 25篇 |
一般理论 | 5篇 |
预防医学 | 525篇 |
眼科学 | 113篇 |
药学 | 614篇 |
中国医学 | 10篇 |
肿瘤学 | 688篇 |
出版年
2024年 | 18篇 |
2023年 | 130篇 |
2022年 | 236篇 |
2021年 | 393篇 |
2020年 | 246篇 |
2019年 | 296篇 |
2018年 | 294篇 |
2017年 | 248篇 |
2016年 | 267篇 |
2015年 | 265篇 |
2014年 | 377篇 |
2013年 | 433篇 |
2012年 | 677篇 |
2011年 | 608篇 |
2010年 | 356篇 |
2009年 | 343篇 |
2008年 | 526篇 |
2007年 | 476篇 |
2006年 | 481篇 |
2005年 | 460篇 |
2004年 | 391篇 |
2003年 | 363篇 |
2002年 | 316篇 |
2001年 | 68篇 |
2000年 | 44篇 |
1999年 | 58篇 |
1998年 | 65篇 |
1997年 | 52篇 |
1996年 | 35篇 |
1995年 | 38篇 |
1994年 | 23篇 |
1993年 | 17篇 |
1992年 | 24篇 |
1991年 | 13篇 |
1990年 | 12篇 |
1989年 | 7篇 |
1988年 | 10篇 |
1987年 | 7篇 |
1986年 | 6篇 |
1985年 | 9篇 |
1984年 | 4篇 |
1983年 | 2篇 |
1982年 | 2篇 |
1977年 | 4篇 |
1942年 | 1篇 |
1907年 | 2篇 |
1906年 | 3篇 |
1905年 | 3篇 |
1904年 | 2篇 |
1903年 | 4篇 |
排序方式: 共有8720条查询结果,搜索用时 15 毫秒
991.
992.
Oliver Gautschi Sacha I. Rothschild Qiyu Li Klazien Matter-Walstra Alfred Zippelius Daniel C. Betticher Martin Früh Rolf A. Stahel Richard Cathomas Daniel Rauch Miklos Pless Solange Peters Patrizia Froesch Thilo Zander Martina Schneider Christine Biaggi Nicolas Mach Adrian F. Ochsenbein 《Clinical lung cancer》2017,18(3):303-309
Background
Pemetrexed and bevacizumab as single agents have been approved for maintenance therapy after platinum-based induction in patients with advanced nonsquamous non–small-cell lung cancer. It is currently unknown whether bevacizumab plus pemetrexed is superior to pemetrexed alone.Patients and Methods
We conducted a nonrandomized phase II trial with 2 sequential cohorts. In the first cohort, 77 patients were treated with 4 cycles of cisplatin, bevacizumab, and pemetrexed every 3 weeks, followed by bevacizumab plus pemetrexed maintenance until progression. In the second cohort, we treated 52 patients without bevacizumab, using maintenance with pemetrexed alone. Progression-free survival (PFS), overall survival (OS), overall response rate (ORR), adverse events, and the treatment costs of the 2 cohorts were compared.Results
The median PFS from the time of registration was 6.9 months in cohort 1 and 5.6 months in cohort 2. The ORR was 62.3% in cohort 1% and 44.2% in cohort 2. The PFS (hazard ratio, 0.7; 95% confidence interval [CI], 0.5-1.0; P = .041) and ORR (odds ratio, 2.1; 95% CI, 1.0-4.3; P = .049) were better in cohort 1 than in cohort 2. No OS difference was found (hazard ratio, 1.0; 95% CI, 0.7-1.6; P = .890) after a median follow-up period of 47 months for cohort 1 and 27 months for cohort 2. The rate of grade ≥ 3 adverse events was greater in cohort 1. The treatment costs per patient were on average 1.4 times greater for cohort 1.Conclusion
The addition of bevacizumab increased the ORR and PFS, but not OS, in our nonrandomized trial. Furthermore, the addition of bevacizumab was associated with greater toxicity and higher costs. 相似文献993.
994.
A. Martina 《Langenbeck's archives of surgery / Deutsche Gesellschaft fur Chirurgie》1903,71(5-6):582-593
Ohne Zusammenfassung
(Mit 1 Abbildung.) 相似文献
995.
A. Martina 《Langenbeck's archives of surgery / Deutsche Gesellschaft fur Chirurgie》1906,83(3-4):317-323
Ohne Zusammenfassung
(Mit 3 Abbildungen.) 相似文献
996.
997.
Michael J. M. Groh Georg Michelson Joanna Harazny Martina Groh Klaus Koschinsky 《Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft》1999,250(3):706-710
Hintergrund: Viele der antiglaukomat?sen Medikamente beeinflussen den okul?ren Blutflu?. Die Blutflu?ver?nderungen in der vorderen Uvea sind in der Literatur beschrieben. über den Effekt von Antiglaukomatosa auf den Blutflu? des hinteren Augenpols wird in neuerer Zeit vermehrt berichtet. Wir pr?sentieren eine Placebo-kontrollierte Studie mit Blick auf den kurz- und mittelfristigen Einflu? von topisch appliziertem Dipivefrin 0,1 % auf den retinalen und papill?ren Blutflu?. 相似文献
998.
Marian Branny MD PhD Pavel Osmancik MD PhD Petr Kala MD PhD Martin Poloczek MD Dalibor Herman MD PhD Petr Neuzil MD CSc Pavel Hala MD Milos Taborsky MD CSc Josef Stasek MD PhD Ludek Haman MD PhD Jan Chovancik MD Pavel Cervinka MD PhD Jiri Holy MD Tomas Kovarnik MD PhD David Zemanek MD PhD Stepan Havranek MD PhD Vlastimil Vancura MD PhD Petr Peichl MD PhD Petr Tousek MD PhD Marek Hozman MD Veronika Lekesova MD Jiri Jarkovsky RNDr PhD Martina Novackova Mgr. Klara Benesova Mgr Petr Widimsky MD DrSc Vivek Y. Reddy MD the PRAGUE- Trial Investigators 《Journal of cardiovascular electrophysiology》2023,34(9):1885-1895
Introduction
Observational studies have shown low bleeding rates in patients with atrial fibrillation (AF) treated by left atrial appendage closure (LAAC); however, data from randomized studies are lacking. This study compared bleeding events among patients with AF treated by LAAC and nonvitamin K anticoagulants (NOAC).Methods
The Prague-17 trial was a prospective, multicenter, randomized trial that compared LAAC to NOAC in high-risk AF patients. The primary endpoint was a composite of a cardioembolic event, cardiovascular death, and major and clinically relevant nonmajor bleeding (CRNMB) defined according to the International Society on Thrombosis and Hemostasis (ISTH).Results
The trial enrolled 402 patients (201 per arm), and the median follow-up was 3.5 (IQR 2.6–4.2) years. Bleeding occurred in 24 patients (29 events) and 32 patients (40 events) in the LAAC and NOAC groups, respectively. Six of the LAAC bleeding events were procedure/device-related. In the primary intention-to-treat analysis, LAAC was associated with similar rates of ISTH major or CRNMB (sHR 0.75, 95% CI 0.44–1.27, p = 0.28), but with a reduction in nonprocedural major or CRNMB (sHR 0.55, 95% CI 0.31–0.97, p = 0.039). This reduction for nonprocedural bleeding with LAAC was mainly driven by a reduced rate of CRNMB (sHR for major bleeding 0.69, 95% CI 0.34–1.39, p = .30; sHR for CRNMB 0.43, 95% CI 0.18–1.03, p = 0.059). History of bleeding was a predictor of bleeding during follow-up. Gastrointestinal bleeding was the most common bleeding site in both groups.Conclusion
During the 4-year follow-up, LAAC was associated with less nonprocedural bleeding. The reduction is mainly driven by a decrease in CRNMB. 相似文献999.
Nadja R. Brun Margreet M. T. Beenakker Ellard R. Hunting Dieter Ebert Martina G. Vijver 《Nanotoxicology》2017,11(8):1059-1069
Nanoplastic debris is currently expected to be ubiquitously distributed in aquatic environments and an emerging environmental issue affecting organisms across trophic levels. While ingestion of particles receives most attention, other routes of uptake and cellular accumulation remain unexplored. Here, the planktonic filter feeder Daphnia magna was used to track routes of uptake and target tissues of polystyrene nanoparticles (PSNPs). A sublethal concentration of 5?mg L?1 fluorescent PSNPs (25?nm) was used to monitor accumulation in adult animals as well as their embryos in the open brood pouch. A time series throughout embryonic development within the brood pouch revealed accumulation of PSNP in or on lipophilic cells in the early stages of embryonic development while the embryo is still surrounded by a chorion and before the beginning of organogenesis. In contrast, PSNP particles were neither detected in the gut epithelium nor in lipid droplets in adults. An ex vivo exposure of embryos to PSNP demonstrated a similar accumulation of PSNP in or on lipophilic cells, illustrating the likelihood of brood pouch-mediated PSNP uptake by embryos. By demonstrating embryo PSNP uptake via the brood pouch, data presented here give novel insights in bioaccumulation of nanoparticles and likely other lipophilic contaminants. Since this uptake route can occur within a diverse array of aquatic organisms, this study warrants consideration of brood pouch-mediated accumulation in efforts studying the hazards and risks of nanoparticle contamination. 相似文献
1000.
Ping Wang Martina Anton Frank L. Graham Silvia Bacchetti 《Somatic Cell and Molecular Genetics》1995,21(6):429-441
An adenovirus vector (AdCre1) expressing Cre recombinase has been used to induce recombination betweenloxP sites in human chromosomes. G418 resistant cells with oneloxP site, generated by transfection with a plasmid containingloxP between the SV40 promoter and the G418 resistance (neo) gene, were infected with AdCre1 and transfected with a plasmid containingloxP adjacent to a promoterless hisD gene. This resulted in integration of hisD downstream of the SV40 promoter with gain of
histidinol and loss of G418 resistance. Since AdCre1 is non-replicating and Cre expression transient, histidinol resistant
cells containing the hisD gene flanked byloxP sites were stable. Reinfection of these cells with AdCre1 induced excision of hisD in over 90% of infected cells. This high
efficiency of site-specific recombination suggests that AdCre1 may be exploited for temporal and tissue-specific regulation
of gene expression and for chromosome engineering in vitro and in animals. 相似文献